Healthcare provider profile · identity verified

Blesilda Hidalgo Olfato, MD

Internal Medicine · SARASOTA, FL · NPI 1922186485

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	304	105
Eliquis	Apixaban	208	45
Levothyroxine Sodium	Levothyroxine Sodium	208	73
Amlodipine Besylate	Amlodipine Besylate	147	55
Metoprolol Tartrate	Metoprolol Tartrate	141	49
Furosemide	Furosemide	125	33
Potassium Chloride	Potassium Chloride	122	42
Lisinopril	Lisinopril	115	28
Quetiapine Fumarate	Quetiapine Fumarate	115	27
Trazodone Hcl	Trazodone Hcl	111	27
Gabapentin	Gabapentin	110	41
Donepezil Hcl	Donepezil Hcl	105	27
Divalproex Sodium	Divalproex Sodium	99	18
Metoprolol Succinate	Metoprolol Succinate	99	41
Tamsulosin Hcl	Tamsulosin Hcl	99	33
Losartan Potassium	Losartan Potassium	95	37
Mirtazapine	Mirtazapine	92	33
Memantine Hcl	Memantine Hcl	91	18
Omeprazole	Omeprazole	84	32
Pantoprazole Sodium	Pantoprazole Sodium	68	28
Clopidogrel	Clopidogrel Bisulfate	67	22
Metformin Hcl	Metformin Hcl	63	14
Escitalopram Oxalate	Escitalopram Oxalate	57	13
Famotidine	Famotidine	53	15
Januvia	Sitagliptin Phosphate	51	suppressed
Sertraline Hcl	Sertraline Hcl	51	17
Carvedilol	Carvedilol	48	15
Duloxetine Hcl	Duloxetine Hcl	47	19
Allopurinol	Allopurinol	46	15
Buspirone Hcl	Buspirone Hcl	46	15
Simvastatin	Simvastatin	45	12
Spironolactone	Spironolactone	42	14
Warfarin Sodium	Warfarin Sodium	41	11
Citalopram Hbr	Citalopram Hydrobromide	35	12
Ezetimibe	Ezetimibe	35	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Xarelto	Rivaroxaban	33	suppressed
Bumetanide	Bumetanide	32	14
Prednisone	Prednisone	31	11
Amiodarone Hcl	Amiodarone Hcl	30	14
Levetiracetam	Levetiracetam	28	suppressed
Ondansetron Hcl	Ondansetron Hcl	28	25
Rosuvastatin Calcium	Rosuvastatin Calcium	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	11
Midodrine Hcl	Midodrine Hcl	25	13
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	22	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	22	12
Montelukast Sodium	Montelukast Sodium	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	15
Digoxin	Digoxin	20	suppressed
Finasteride	Finasteride	20	12
Hydralazine Hcl	Hydralazine Hcl	20	11
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Jardiance	Empagliflozin	19	suppressed
Tramadol Hcl	Tramadol Hcl	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	13
Latanoprost	Latanoprost	18	suppressed
Olanzapine	Olanzapine	18	suppressed
Sucralfate	Sucralfate	18	suppressed
Baclofen	Baclofen	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Nystatin	Nystatin	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	12
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Atenolol	Atenolol	13	suppressed
Cephalexin	Cephalexin	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Permethrin	Permethrin	13	suppressed
Trintellix	Vortioxetine Hydrobromide	13	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Effer-K	Potassium Bicarbonate/Cit Ac	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Glipizide	Glipizide	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Folic Acid	Folic Acid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error